|
|
Br J Ophthalmol. 2000 July; 84(7): 687–691. doi: 10.1136/bjo.84.7.687. | PMCID: PMC1723533 |
In vitro antibiotic resistance in bacterial keratitis in London S. Tuft and M. Matheson Moorfields Eye Hospital, London EC1V 2PD. Email: stuft1/at/cs.com AIM—To document changes in the profile of bacterial isolates from cases of keratitis and changes in their susceptibility to first line antibiotic therapies. METHODS—A retrospective review was performed of all bacterial isolates from cases of keratitis seen between 1984 and 1999. In vitro laboratory susceptibilities to antibiotics were determined by the Kirby-Bauer disc diffusion method. The number of isolates, changes in the proportion of bacterial types, and the number that were fully resistant to monotherapy (ofloxacin), dual therapy (gentamicin and cefuroxime), and prophylactic treatment (chloramphenicol) were calculated. RESULTS—There were 1312 bacterial isolates over 16 years. Gram positive bacteria accounted for 54.7% of isolates and Staphylococcus species (33.4%) were the most frequently isolated organisms. During the study period there has been an increase in the proportion of Pseudomonas species isolates but no overall increase in the proportion of Gram negative isolates. There has not been an increase in the proportion of isolates resistant to ofloxacin since 1995 or an increase in resistance to the combination of gentamicin and cefuroxime. However, since 1984 there has been a significant increase in proportion of Gram negative organisms resistant to chloramphenicol (p=0.0019). CONCLUSIONS—An increase in the in vitro resistance of organisms to first line therapies for bacterial keratitis has not been observed. An increased resistance to chloramphenicol indicates that this drug is unlikely to provide prophylactic cover when Gram negative infection is a risk. Continued monitoring for the emergence of antibiotic resistance is recommended.
The Full Text of this article is available as a PDF (135K). These references are in PubMed. This may not be the complete list of references from this article. - Baum JL. Initial therapy of suspected microbial corneal ulcers. I. Broad antibiotic therapy based on prevalence of organisms. Surv Ophthalmol. 1979 Sep–Oct;24(2):97–105. [PubMed]
- Jones DB. Initial therapy of suspected microbial corneal ulcers. II. Specific antibiotic therapy based on corneal smears. Surv Ophthalmol. 1979 Sep–Oct;24(2):97–105-16. [PubMed]
- Petroutsos G, Guimaraes R, Pouliquen Y. The effect of concentrated antibiotics on the rabbit's corneal epithelium. Int Ophthalmol. 1984 Jun;7(2):65–69. [PubMed]
- Bowe BE, Snyder JW, Eiferman RA. An in vitro study of the potency and stability of fortified ophthalmic antibiotic preparations. Am J Ophthalmol. 1991 Jun 15;111(6):686–689. [PubMed]
- Davison CR, Tuft SJ, Dart JK. Conjunctival necrosis after administration of topical fortified aminoglycosides. Am J Ophthalmol. 1991 Jun 15;111(6):690–693. [PubMed]
- Chin NX, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984 Mar;25(3):319–326. [PubMed]
- Neu HC. Microbiologic aspects of fluoroquinolones. Am J Ophthalmol. 1991 Oct;112(4 Suppl):15S–24S. [PubMed]
- McDermott ML, Tran TD, Cowden JW, Buggé CJ. Corneal stromal penetration of topical ciprofloxacin in humans. Ophthalmology. 1993 Feb;100(2):197–200. [PubMed]
- Diamond JP, White L, Leeming JP, Bing Hoh H, Easty DL. Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration. Br J Ophthalmol. 1995 Jun;79(6):606–609. [PubMed]
- Price FW, Jr, Whitson WE, Collins KS, Gonzales JS. Corneal tissue levels of topically applied ciprofloxacin. Cornea. 1995 Mar;14(2):152–156. [PubMed]
- O'Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 1995 Oct;113(10):1257–1265. [PubMed]
- Hyndiuk RA, Eiferman RA, Caldwell DR, Rosenwasser GO, Santos CI, Katz HR, Badrinath SS, Reddy MK, Adenis JP, Klauss V. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology. 1996 Nov;103(11):1854–1863. [PubMed]
- Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy. The Ofloxacin Study Group. Ophthalmology. 1997 Nov;104(11):1902–1909. [PubMed]
- Humphreys H, Mulvihill E. Ciprofloxacin-resistant Staphylococcus aureus. Lancet. 1985 Aug 17;2(8451):383–383. [PubMed]
- Wise R. Macrolide progress. J Antimicrob Chemother. 1990 Jul;26(1):5–6. [PubMed]
- Ball P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. J Antimicrob Chemother. 1990 Dec;26 Suppl F:165–179. [PubMed]
- Raviglione MC, Boyle JF, Mariuz P, Pablos-Mendez A, Cortes H, Merlo A. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother. 1990 Nov;34(11):2050–2054. [PubMed]
- Daum TE, Schaberg DR, Terpenning MS, Sottile WS, Kauffman CA. Increasing resistance of Staphylococcus aureus to ciprofloxacin. Antimicrob Agents Chemother. 1990 Sep;34(9):1862–1863. [PubMed]
- Snyder ME, Katz HR. Ciprofloxacin-resistant bacterial keratitis. Am J Ophthalmol. 1992 Sep 15;114(3):336–338. [PubMed]
- Maffett M, O'Day DM. Ciprofloxacin-resistant bacterial keratitis. Am J Ophthalmol. 1993 Apr 15;115(4):545–546. [PubMed]
- Knauf HP, Silvany R, Southern PM, Jr, Risser RC, Wilson SE. Susceptibility of corneal and conjunctival pathogens to ciprofloxacin. Cornea. 1996 Jan;15(1):66–71. [PubMed]
- Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol. 1996 Jun;121(6):712–715. [PubMed]
- Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology. 1999 Jan;106(1):80–85. [PubMed]
- Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999 Jul;106(7):1313–1318. [PubMed]
- Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology. 1999 Jul;106(7):1319–1323. [PubMed]
- Baum J, Barza M. Topical vs subconjunctival treatment of bacterial corneal ulcers. Ophthalmology. 1983 Feb;90(2):162–168. [PubMed]
- McLeod SD, DeBacker CM, Viana MA. Differential care of corneal ulcers in the community based on apparent severity. Ophthalmology. 1996 Mar;103(3):479–484. [PubMed]
- Vance-Bryan K, Guay DR, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet. 1990 Dec;19(6):434–461. [PubMed]
- Hooper DC, Wolfson JS, Ng EY, Swartz MN. Mechanisms of action of and resistance to ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):12–20. [PubMed]
- Kaatz GW, Seo SM. Mechanism of ciprofloxacin resistance in Pseudomonas aeruginosa. J Infect Dis. 1988 Sep;158(3):537–541. [PubMed]
- Walker S, Diaper CJ, Bowman R, Sweeney G, Seal DV, Kirkness CM. Lack of evidence for systemic toxicity following topical chloramphenicol use. Eye (Lond). 1998;12(Pt 5):875–879. [PubMed]
- Wilhelmus KR, Hyndiuk RA, Caldwell DR, Abshire RL, Folkens AT, Godio LB. 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. The Ciprofloxacin Ointment/Bacterial Keratitis Study Group. Arch Ophthalmol. 1993 Sep;111(9):1210–1218. [PubMed]
|